$10.76 Million in Sales Expected for Agenus Inc (AGEN) This Quarter
Wall Street brokerages expect Agenus Inc (NASDAQ:AGEN) to report sales of $10.76 million for the current quarter, Zacks reports. Two analysts have made estimates for Agenus’ earnings, with the highest sales estimate coming in at $11.52 million and the lowest estimate coming in at $10.00 million. Agenus reported sales of $3.36 million in the same quarter last year, which indicates a positive year over year growth rate of 220.2%. The company is scheduled to announce its next earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that Agenus will report full-year sales of $31.33 million for the current fiscal year, with estimates ranging from $30.15 million to $32.50 million. For the next fiscal year, analysts expect that the company will report sales of $10.85 million, with estimates ranging from $5.70 million to $16.00 million. Zacks Investment Research’s sales averages are an average based on a survey of analysts that follow Agenus.
Agenus (NASDAQ:AGEN) last released its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.16.
AGEN stock traded down $0.01 during trading on Tuesday, hitting $1.98. 1,723,200 shares of the company’s stock traded hands, compared to its average volume of 1,495,582. The firm has a market cap of $242.42 million, a price-to-earnings ratio of -1.58 and a beta of 1.84. The company has a quick ratio of 1.32, a current ratio of 1.32 and a debt-to-equity ratio of -0.11. Agenus has a 1 year low of $1.55 and a 1 year high of $6.19.
Hedge funds have recently modified their holdings of the stock. Northern Trust Corp grew its holdings in Agenus by 4.3% in the second quarter. Northern Trust Corp now owns 1,005,499 shares of the biotechnology company’s stock worth $2,282,000 after purchasing an additional 41,300 shares during the last quarter. Jane Street Group LLC purchased a new position in Agenus in the second quarter worth $101,000. RTW Investments LP grew its holdings in Agenus by 0.7% in the second quarter. RTW Investments LP now owns 9,375,451 shares of the biotechnology company’s stock worth $21,282,000 after purchasing an additional 61,895 shares during the last quarter. BlackRock Inc. grew its holdings in shares of Agenus by 15.7% during the second quarter. BlackRock Inc. now owns 5,717,966 shares of the biotechnology company’s stock valued at $12,980,000 after buying an additional 776,715 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. grew its holdings in shares of Agenus by 9.8% during the second quarter. Schwab Charles Investment Management Inc. now owns 383,085 shares of the biotechnology company’s stock valued at $870,000 after buying an additional 34,065 shares during the last quarter. 35.33% of the stock is currently owned by institutional investors.
Agenus Company Profile
Agenus Inc, a clinical-stage immuno-oncology company, focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; SECANT yeast display, an antibody discovery platform used for the generation of novel monoclonal antibodies; and phage display technologies.
Featured Story: Cash Flow Analysis in Stock Selection
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.